WeVote
Log In

Bill

Bill

A 9245

Requires epinephrine devices for anaphylaxis and staff trained to use them at child day care centers

2025 Regular Session Introduced by Linda Rosenthal

Requires child day care centers to have epinephrine devices on-site and staff trained to use them, enabling immediate anaphylaxis treatment for enrolled children.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · A 9245

Bill Summary: Assembly Bill A 9245

Overview

A 9245, titled “Requires epinephrine devices for anaphylaxis and staff trained to use them at child day care centers,” would require child day care centers to have available epinephrine devices for anaphylaxis and to ensure staff are trained to use them. The bill was introduced on November 7, 2025 and is currently REFERRED TO HEALTH. The primary sponsor is Assembly Member Linda Rosenthal. A Senate companion exists as S 8587.

Key Provisions

  • Epinephrine availability: Child day care centers would be required to have epinephrine devices available on site to treat anaphylaxis.
  • Staff training: Center staff would need to be trained to recognize signs of anaphylaxis and to administer epinephrine using the devices.
  • Scope: Applies specifically to child day care centers within the jurisdiction of the bill (as drafted).

Affected Parties

  • Child day care centers and their administrators
  • Center staff (including teachers and aides)
  • Children enrolled in day care centers
  • Parents/guardians of children enrolled in these centers

Training and Equipment Details

  • Training: Staff must be trained in identifying anaphylaxis and in the proper use of epinephrine devices.
  • Equipment: Epinephrine devices (e.g., epinephrine auto-injectors) must be available on-site at participating centers.

Implementation Timeline and Procedures

  • Status indicates referral to the Health Committee; no specific implementation timeline or effective date is provided in the information available.
  • Details such as procurement processes, maintenance, stock rotation, storage requirements, and who bears costs are not specified in the provided summary.

Enforcement and Compliance

  • Penalties or enforcement mechanisms are not outlined in the provided information.
  • It is common for such bills to include a grace period for centers to come into compliance and to specify penalties for non-compliance, but these elements are not described here.

Fiscal Implications

  • No fiscal impact is stated in the provided summary. If enacted, the bill would likely involve costs related to acquiring epinephrine devices and funding staff training, as well as ongoing replenishment and maintenance.

Legislative Context

  • Related Legislation: S 8587 (companion bill) in the Senate.
  • Status: Referred to Health as of 2025-11-07 (duplicate entry also shows the same referral date).
  • Sponsor: Linda Rosenthal (primary).

What to Watch For

  • Whether the Health Committee advances A 9245 with amendments (e.g., specifying training standards, stock requirements, funding sources, and enforcement).
  • The contents of the Senate companion S 8587 and whether it mirrors or expands on the Assembly proposal.
  • Any fiscal notes, public comment, or stakeholder input that could shape provisions on cost, training timelines, and implementation.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.